^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LY2109761

i
Other names: LY2109761
Company:
Eli Lilly
Drug class:
TGF-β R2 kinase inhibitor, TGF-β RI kinase inhibitor
3d
Mitochondrial-targeted photodynamic therapy combined with TGF-β inhibition potentiates anti-PD-1 therapy in pancreatic ductal adenocarcinoma. (PubMed, J Nanobiotechnology)
To address these challenges, we develop a liposomal nanodrug that co-encapsulates a mitochondrial-targeted photosensitizer (MP) and a TGF-β receptor inhibitor (LY2109761) to synergize PDT with PD-1 checkpoint blockade...In murine PDAC models, this dual-action strategy transforms the immune-cold TME into an immune-inflamed phenotype, sensitizing tumors to PD-1 therapy and leading to pronounced tumor regression and prolonged survival. Our findings present a promising nanodrug-based approach to remodel the fibrotic and immunosuppressive TME of PDAC and enhance immunotherapeutic outcomes.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
LY2109761
1m
CD44 knockdown and TGF‑β inhibition modulate cell proliferation and invasion in claudin‑low breast cancer cells. (PubMed, Oncol Rep)
CD44 was knocked down in claudin‑low breast cancer cell lines (SUM159 and MDA‑MB‑231), and the TGF‑β receptor (TGFBR) inhibitor LY2109761 (LY‑61) was applied for treatment...Although CD44 depletion may increase EMT‑related signaling, invasion was primarily suppressed by TGF‑β blockade, and the combination with CD44 knockdown further enhanced the inhibition of proliferative phenotypes compared with either treatment alone. This dual‑targeting approach warrants further investigation in claudin‑low breast cancer.
Journal
|
CD44 (CD44 Molecule) • CD24 (CD24 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • ANXA5 (Annexin A5)
|
LY2109761
3ms
Role of the TGF-β/SMAD pathway in tumor radioresistance to boron neutron capture therapy (BNCT) in a human cell line of colon adenocarcinoma. (PubMed, Appl Radiat Isot)
The activation of the TGF-β/SMAD pathway and its interaction with the DNA repair via through ATR transductor was demonstrated. LY2109761 could act as a radiosensitizer for BNCT.
Preclinical • Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • SMAD7 (SMAD Family Member 7)
|
LY2109761
5ms
EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma. (PubMed, Eur J Med Res)
Human LUAD cells HCC827 and H1975 were exposed to different doses of osimertinib or erlotinib to generate TKI-resistant cell lines. Notably, the LY2109761 treatment reduced TKI resistance and diminished expansion, migration, and stemness in cancer cells induced by EMP3 overexpression. In conclusion, this study indicates that EMP3, upregulated upon EMT, contributes to EGFR-TKI resistance in LUAD cells.
Journal
|
EGFR (Epidermal growth factor receptor) • TGFB1 (Transforming Growth Factor Beta 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
EGFR mutation
|
Tagrisso (osimertinib) • erlotinib • LY2109761
5ms
Enhancing the therapeutic efficacy of gemcitabine in bladder cancer through TGF-β1 inhibition and pluronic F-127-based microsphere delivery. (PubMed, J Biol Eng)
The present research was designed to explore the impact of TGF-β1 inhibitors (LY2109761 and LY3200882) with or without gemcitabine on bladder cancer cells and to develop Pluronic F-127-based microspheres (MSs) for drug delivery. Systemic and local bladder toxicity assessments in mice demonstrated the in vivo safety of drug-loaded MSs. This study concludes that combining TGF-β1 inhibitors with gemcitabine in Pluronic F-127-based MSs enhances therapeutic efficacy against bladder cancer, promoting apoptosis, inhibiting cell invasion, and reducing tumor growth and metastasis while maintaining safety.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
gemcitabine • LY2109761 • LY3200882
1year
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancer. (PubMed, Bioeng Transl Med)
Here, we evaluated combination treatments using experimental TGFR inhibitors (TGFβi), SB525334 (SB), and LY2109761 (LY) with paclitaxel (PTX) chemotherapy. Genetic profiling of the tumors revealed differences in the expression levels of genes associated with TGFβ, epithelial to mesenchymal transition (EMT), TLR-4, and Bcl2 signaling, alluding to the susceptibility to specific gene signatures to the treatment. Taken together, our study suggests that TGFβi and PTX combination therapy using high-capacity POx micelle delivery provides a robust antitumor response in multiple TNBC subtype mouse models.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4) • TGFBI (Transforming Growth Factor Beta Induced)
|
paclitaxel • LY2109761
1year
AMIGO2 enhances the invasive potential of colorectal cancer by inducing EMT. (PubMed, Cancer Gene Ther)
Activation of the TGFβ/Smad signaling pathway was found involved in AMIGO2-induced EMT, and treatment with the TGFβ receptor inhibitor LY2109761 suppressed AMIGO2-induced EMT...These results suggest that the nuclear translocation of AMIGO2 induces EMT to promote CRC invasion by activating the TGFβ/Smad signaling pathway. Thus, AMIGO2 is an attractive therapeutic target for inhibiting EMT and metastatic CRC progression.
Journal
|
HMGB1 (High Mobility Group Box 1) • AMIGO2 (Adhesion Molecule With Ig Like Domain 2)
|
LY2109761
almost2years
Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer. (PubMed, J Cell Mol Med)
To elucidate the underlying mechanism, we compared the efficacy of PFD after pretreatment with either TGF-β1 or a TGF-β receptor inhibitor (LY2109761). Additionally, PFD combined with cisplatin targeted TGF-β1 to inhibit glycolysis during EMT and enhanced the chemosensitization of A549 and H1299 cells. The magnitude of the anticancer effect exhibited by PFD was intricately linked to its metabolic properties.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
cisplatin • LY2109761
2years
Primary cilium participates in radiation-induced bystander effects through TGF-β1 signaling. (PubMed, J Cell Physiol)
The TGF-β1 signaling was interfered by LY2109761, a TGF-β receptor 1 (TβR1) inhibitor, or TGF-β1 neutral antibody...IFT88 siRNA or KIF3a siRNA impaired PC formation resulted in an aggravated DNA damage in bystander cells, while elevated PC formation by CytoD or STIL siRNA resulted in a decrease of DNA damage. Furthermore, TGF-β1 induced more DNA damages in S phases cells which showed lower PC formation rate and less DNA damages in G /G phase cells which showed higher PC formation rate. This study demonstrates the particular role of primary cilia during RCM induced DNA damages through TGF-β1 signaling restriction and thereby provides a functional link between primary cilia and RIBEs.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
LY2109761
2years
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. (PubMed, Front Med)
Collectively, although TEXs lead to the initial activation of CAR T-cells, the effect of TEXs suppressed CAR T-cells, which can be rescued by LY2109761. A treatment regimen combining CAR T-cell therapy and TGF-β inhibitors might be a novel therapeutic strategy for refractory and relapsed B-cell lymphoma.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
|
LAG3 expression • HAVCR2 expression
|
LY2109761
over2years
Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer. (PubMed, Int J Immunopathol Pharmacol)
Totally, we initially identified the smoking-related epigenetic modifications in bladder cancer and constructed a corresponding prognostic model, which was also linked to disparate sensitivities to chemotherapeutics. Our findings would provide novel insights into the carcinogenesis, prognosis, and therapies in bladder cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
|
cisplatin • gemcitabine • buparlisib (AN2025) • LY2109761